The FDA has approved iCAD’s Xoft Axxent electronic brachytherapy system, which delivers high dose rate brachytherapy for intracavitary treatment of cancer of the uterus, cervix, endometrium and vagina.

More stringent criteria may be needed for African American men with prostate cancer when considering active surveillance of the disease due to a higher risk of advanced stage cancer, according to a study published in the March issue of Urology. Prevalence of advanced stage cancer in African American men who were considered to have a low-risk prostate cancer on initial consultation but chose to undergo a radical prostatectomy was nearly twice that of Caucasian men, reported authors Isaac Yi Kim, MD, PhD, of The Cancer Institute of New Jersey, New Brunswick, and colleagues.

The first-ever study to analyze 25 years of follow-up data after radiation therapy (RT) treatment for prostate cancer patients has found the treatment controls disease effectively long-term, and if prostate specific antigen (PSA) is less than 0.2 ng/ml at 15 years post-treatment, later recurrence is very unlikely.

As diagnosis and management of cancer of unknown primary (CUP) sites has become more personalized, a multidisciplinary approach among oncologists, pathologists and radiologists is essential, according to a review article published in the March issue of the American Journal of Roentgenology.

An update to a National Cancer Institute (NCI) lung cancer risk prediction model was found to be more sensitive than the National Lung Screening Trial (NLST) criteria for lung-cancer detection, according to a study published Feb. 21 in the New England Journal of Medicine.

Complete implementation of the CT screening protocol used in the National Lung Screening Trial (NLST) could avert 12,250 deaths annually in the U.S., according to a study published online Feb. 25 in CANCER. An accompanying editorial questioneed some implications of nationwide screening in the U.S.

Demographic differences in the use of PET imaging among Medicare beneficiaries with non-small cell lung cancer have persisted since the modality’s approval by Medicare in 1998, according to a study published online Feb. 15 in Radiology.

One consistent prerequisite to a comprehensive lung cancer screening program is the multidisciplinary team. Is the team a barrier to community imaging practices that want to offer lung cancer screening? No, according to N.J.-based Atlantic Medical Imaging. Its lung cancer screening program demonstrates how imaging providers can adapt and replicate the essential multidisciplinary team.